Can GLP-1 drugs slow ageing? Mouse study shows promise
2026-09-02 08:00Science🔥 26.9 heat score
1sources
1days unfolding
26.9heat score
4mentions
SummaryAI generated
After receiving GLP-1 anti-obesity therapy, the average lifespan of elderly female mice increased by 12% to 834 days, which is better than the 742 days of the untreated control group. The treatment group showed better coordination, muscle function, and glucose processing; multiple aging-related cellular and molecular changes were significantly reduced, and self-induced weight loss was 24%. The study indicates that despite the same intake, the treated group had better health indicators. This research was published in the journal Nature, suggesting that GLP-1 drugs may have potential to delay aging, but further human clinical trials are needed to verify this.
Female aged mice treated with GLP-1-class anti-obesity drugs lived an average of 834 days, a 12% increase compared to the untreated control group (742 days). Treated mice showed improved coordination, muscle function, and glucose metabolism, along with significant reductions in multiple age-related cellular and molecular changes, such as inflammation. The drug enabled mice to self-regulate food intake by 24%. Researchers also included a group of mice with identical food intake but no drug treatment; both groups had similar lifespans, yet the GLP-1-treated group exhibited superior performance across multiple health indicators. This study, published in Nature, suggests that GLP-1 drugs may have potential in slowing aging, though current findings remain preliminary and require further validation through human clinical trials.